KARINE KIRAKOSYAN: Open Payments
NPI 1427092071 · BURBANK, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,804 in 85 payments from 17 companies in 2025. Trend: 2023 $1,522 · 2024 $1,648 · 2025 $1,804
Food & beverage: $1,804
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 16 | $455 |
| ABBVIE INC. | 14 | $292 |
| Sumitomo Pharma America, Inc. | 10 | $262 |
| Amgen Inc. | 18 | $164 |
| GlaxoSmithKline, LLC. | 7 | $147 |
| PFIZER INC. | 3 | $79 |
| Ardelyx, Inc. | 3 | $73 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 2 | $56 |
| Lundbeck LLC | 2 | $48 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 2 | $42 |
Products named: BREZTRI, GEMTESA, QULIPTA, TRELEGY ELLIPTA, AIRSUPRA, JARDIANCE, OTEZLA, NURTEC ODT.
Industry payments across CA — which companies pay providers there.
